Dana-Farber Cancer Institute
Boston, MA
Accepting patients
ACCELERATE
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- Allogeneic Stem Cell Transplant
- Post-Allogeneic Stem Cell Transplant
- Phase 2
Accepting patients
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
- Natural Killer Cells
- Chemotherapy
- Phase 1
Accepting patients
LP-118
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory NHL, RT, MM, T-PLL, Acute Leukemia (AML, ALL), MDS, MDS/MPN, and MF
- BCL-2 Inhibitor
- Bcl/xL Inhibitor
- Phase 1
- Dipeptidyl Peptidase 4 (DPP-4) Inhibitor
- Phase 1
Accepting patients
AZTOUND
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
- DNMT1 Inhibitor
- Phase 2/3
- Has results
Accepting patients
Eganelisib
A Phase 1b Open-Label Study to Evaluate the Safety and Tolerability of Eganelisib as Monotherapy and in Combination With Cytarabine in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- PI3K Inhibitor
- Randomization
- Phase 1
Accepting patients
MGD024
A Phase 1, First-in-Human, Dose Escalation Study of MGD024, a CD123 x CD3 Bispecific DART Molecule, in Patients With Select Relapsed or Refractory Hematologic Malignancies
- Bispecific Antibody
- Phase 1
Accepting patients
TRX-103
Phase I, First in Human, Open Label Study to Evaluate Safety and Tolerability of TRX103 Cells in Subjects With Hematological Malignancies Undergoing HLA-mismatched Related or Unrelated Hematopoietic Stem Cell Transplantation (HSCT)
- T Cell (Allogeneic)
- Post-Allogeneic Stem Cell Transplant
- Phase 1
Accepting patients
IS-free Treg Stem Cell Transplant
A Pilot/Phase 1 Study of Immunosuppression-free Regulatory T-cell Graft-engineered Haploidentical Hematopoietic Cell Transplantation in Relapsed/Refractory AML/MDS
- Allogeneic Stem Cell Transplant
- Phase 1
Accepting patients
PedAL Screening
Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias
- Phase 1/2